Sharps Technology Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedMarch 31, 2026 ☐TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number001-41355 Sharps Technology, Inc.(Exact name of registrant as specified in its charter) 82-3751728 (I.R.S. EmployerIdentification No.) State or other jurisdictionof incorporation or organization (Address of principal executive offices) (Zip Code) (631) 574 -4436(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Common Stock, $0.0001 par valueCommon Stock Purchase Warrants NASDAQ Capital MarketNASDAQ Capital Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerNon-accelerated filer ☐Accelerated filer☒Smaller reporting companyEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May 8, 2026, 42,322,168 shares of the registrant’s common stock, par value $.0001 per share, were issued and outstanding. TABLE OF CONTENTS PART I FINANCIAL INFORMATIONITEM 1.FINANCIAL STATEMENTS (Unaudited)Condensed Consolidated Balance SheetsF-1Condensed Consolidated Statements of OperationsF-2Condensed Consolidated Statement of Comprehensive Income (Loss)F-3Condensed Consolidated Statements of Stockholders’ EquityF-4Condensed Consolidated Statements of Cash FlowsF-5Notes to the Condensed Consolidated Financial StatementsF-6ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFOPERATIONS3ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK8ITEM 4.CONTROLS AND PROCEDURES8PART II OTHER INFORMATIONITEM 1.LEGAL PROCEEDINGS9ITEM 1A.RISK FACTORS9ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS9ITEM 6.EXHIBITS13SIGNATURES14 SHARPS TECHNOLOGY, INC.CONDENSED CONSOLIDATED BALANCE SHEETS SHARPS TECHNOLOGY, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSFOR THE THREE MONTHS ENDED MARCH 31(UNAUDITED) SHARPS TECHNOLOGY, INC.CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSSFOR THE THREE MONTHS ENDED MARCH 31(UNAUDITED) SHARPS TECHNOLOGY, INC.CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITYFOR THE THREE MONTHS ENDED MARCH 31, 2025(Unaudited) SHARPS TECHNOLOGY, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE THREE MONTHS ENDED MARCH 31(UNAUDITED) SHARPS TECHNOLOGY, INC.NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTSFOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025 Note 1. Description of Business Nature of Business Sharps Technology, Inc. (“Sharps” or the “Company”) is a medical device sales and distribution enterprise engaged in the marketingand distribution of syringe products and related drug-delivery systems. Previously, the Company was also focused on design andmanufacture of a portfolio of conventional and safety syringes. On August 24, 2025, the Company adopted a digital commodity treasury strategy focused on accumulating Solana (“SOL”), the nativedigital commodity of the Solana blockchain. On October 6, 2025, the Company entered into definitive agreements, including a bill of sale, assignment and assumption agreementproviding for the transfer by the Company of certain assets, and a contract for the transfer of business share providing for theassignment by the Company of all of the Company’s right, title and interest in and to the issued and outstanding shares of SafegardMedical Kft, the Hungarian subsidiary, which is reflected in the accompanying financial statements as a discontinued operation. As of October 6, 2025, with the ownership transfer of Safegard Medical Kft complete, the Company disco